Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
LEO Pharma announced that Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension has been approved for the treatment of plaque psoriasis of the scalp in patients aged 12–17 years. This is the first approved combination treatment for adolescents aged ≥12 years with scalp plaque psoriasis.
Taclonex Topical Suspension is already indicated for treatment of plaque psoriasis of the scalp and body in adults aged ≥18 years. It combines the pharmacological effects of calcipotriene hydrate, a synthetic vitamin D3 analog, and betamethasone dipropionate, a corticosteroid. However, while their pharmacologic and clinical effects are known, the exact mechanisms of their actions in psoriasis vulgaris are unknown.
RELATED: Psoriasis Patient Information Fact Sheet
Taclonex Topical Suspension is available as a 0.005%/0.064% strength in 60g and 120g bottles.
For more information call (877) 494-4536 or visit Taclonex.com.
